Based on this study, the use of DC-SIGN ligands in combination with TLR4 ligands would serve as excellent antigen targeting platforms to enhance the antigen cross-presentation in DC-based anti-tumor vaccination strategies. The gene discussed is CD209; the disease is neoplasm.